Industry

Pfizer licenses three in vivo CAR-T therapies from Starna

Pfizer gains rights outside Greater China to three early-stage CAR-T therapies being developed for autoimmune diseases.

Reported by 3 outlets Thursday, November 19, 2026

Cancer cells under a fluorescence microscope
Photo: CC0

Pfizer has licensed rights to three preclinical in vivo CAR-T programs from Starna Therapeutics, a China-based company. The therapies are being developed for autoimmune diseases. Pfizer will pay $330 million upfront and could pay up to $2.3 billion more in development and commercial milestones, plus royalties on sales of approved products.

Starna’s approach uses RNA to reprogram cells inside the body. Pfizer will lead clinical development outside Greater China and said it plans to manufacture the products for clinical trials at its U.S. facilities. The specific targets and indications have not been disclosed.

Reporting on this story

More top stories

Infectious disease

U.S. loses measles elimination status after 26 years

The U.S. lost measles elimination status after continuous local transmission persisted for 12 months, according to reports on the Pan American Health Organization decision.

Reported by 5 outlets

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.